Roche Group member Genentech has entered a multi-year strategic generative artificial intelligence (AI)-powered research partnership with NVIDIA to expedite the discovery and development of drugs.

Genentech started working on PI3K nearly two decades ago ... “If we can add a PI3K-mutation drug to first-line therapy,” ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Like most of its peers in the biopharma sector, Genentech has been working on AI-powered technologies for drug discovery and development, coming up with a proprietary set of algorithms and other ...

Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

You can also read Eli Lilly chief scientist Daniel M. Skovronsky on fallacies surrounding patents, drug discovery, and affordability, Sandoz CEO Richard Saynor on what the 2024 conversation is ...

Genentech, a drug company, makes bevacizumab, ranibizumab, and faricimab. This company helps patients cover the cost of their products through the Genentech Patient Foundation. If you have ...

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...